polatuzumab vedotin

consists of an anti-CD79B monoclonal antibody conjugated to monomethyl auristatin E

Also Known As:

ACD-79B-VCMMAE; ACD-79BVCMMAE; ACD79B-VCMMAE; DCDS-4501A; DCDS4501A; FCU-2711; FCU2711; Polivy; RG-7596; RG7596; RO-5541077-000; RO-5541077000; RO5541077-000; polatuzumab vedotin-PIIQ

Networked: 120 relevant articles (7 outcomes, 29 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hirata, Jamie: 9 articles (01/2022 - 01/2019)
2.	Lu, Dan: 8 articles (12/2020 - 06/2015)
3.	Salles, Gilles: 6 articles (01/2022 - 06/2015)
4.	Assouline, Sarit: 5 articles (01/2022 - 06/2015)
5.	Sehn, Laurie H: 5 articles (01/2022 - 06/2015)
6.	Agarwal, Priya: 5 articles (12/2020 - 01/2020)
7.	Dere, Randall C: 5 articles (12/2020 - 06/2015)
8.	Girish, Sandhya: 5 articles (12/2020 - 01/2020)
9.	Li, Chunze: 5 articles (12/2020 - 01/2020)
10.	Lu, Tong: 5 articles (12/2020 - 01/2020)

Related Diseases

1.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/01/2021 - "The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. " 10/20/2023 - "This ethnic sensitivity analysis used data from the phase III POLARIX study (NCT03274492) to assess polatuzumab vedotin pharmacokinetics (PKs) in Asian versus non-Asian patients with previously untreated diffuse large B-cell lymphoma and examined the appropriateness of extrapolating global study findings to Asian patients. " 10/01/2020 - "Aim: To evaluate the cost-effectiveness of polatuzumab vedotin (pola) + bendamustine + rituximab (BR) in relapsed/refractory diffuse large B-cell lymphoma based on the GO29365 trial from a US payer's perspective. " 01/01/2019 - "Preliminary clinical activity in newly diagnosed diffuse large B-cell lymphoma seems promising and encouraged a phase 3 trial comparing polatuzumab vedotin with R-CHP to R-CHOP. " 01/01/2019 - "Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study."
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/01/2021 - "A phase 1 dose-escalation study of polatuzumab vedotin (pola) was conducted to assess safety, pharmacokinetics and preliminary antitumor activity of pola in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma. " 01/01/2021 - "Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study." 01/01/2023 - "Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma." 12/01/2020 - "The established two-analyte integrated population pharmacokinetic model was applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of polatuzumab vedotin (pola) in patients with non-Hodgkin lymphoma (NHL) following bodyweight-based dosing. " 12/01/2020 - "Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma."
3.	B-Cell Lymphoma (Lymphoma, B Cell) 10/01/2022 - "A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy." 01/01/2022 - "Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma." 01/01/2021 - "Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas." 01/01/2021 - "Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis." 12/01/2020 - "Polatuzumab vedotin for B-cell lymphoma."
4.	Neurolymphomatosis 01/01/2023 - "Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma."
5.	Neoplasms (Cancer) 01/01/2020 - "Polatuzumab Vedotin: a New Target for B Cell Malignancies." 09/01/2019 - "Polatuzumab vedotin is being developed by Genentech (a subsidiary of Roche) for the treatment of haematological malignancies. " 01/01/2023 - "ABC3315 increased the IC50 of MMAE against human cancer cell lines by > 500-fold with no impact on the cytotoxicity of MMAE ADCs, including polatuzumab vedotin (PV) and trastuzumab-vc-MMAE (TvcMMAE). " 01/01/2023 - "Polatuzumab vedotin, marketed under the trade name POLIVY®, is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E) to B cells, resulting in anti-cancer activity against B-cell malignancies. " 11/01/2012 - "These instruments are the EORTC QOL-C30 and QLQ-BR23 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer Module), the FACT-B (Functional Assessment of Cancer Therapy-Breast Cancer), the SLDS-BC (Satisfaction with Life Domains Scale for Breast Cancer), the BIBCQ (Body Image after Breast Cancer Questionnaire), the HIBS (Hopwood Body Image Scale), the PBIS (Polivy Body Image Scale), the MBROS (Michigan Breast Reconstruction Outcomes Study) Satisfaction and Body Image Questionnaires, the BREAST-Q, the BCTOS (Breast Cancer Treatment Outcome Scale), the BCQ, the FACT-ES (Functional Assessment of Cancer Therapy-Endocrine System), the MAS (Mastectomy Attitude Scale), and the Breast Cancer Prevention Trial Symptom Checklist (BCPT). "

Related Drugs and Biologics

1.	Rituximab (Mabthera)
2.	Doxorubicin (Adriamycin)
3.	Cyclophosphamide (Cytoxan)
4.	Prednisone (Sone)
5.	Vincristine (Oncovin)
6.	Immunoconjugates (Immunoconjugate)
7.	Bendamustine Hydrochloride
8.	monomethyl auristatin E
9.	pinatuzumab vedotin
10.	obinutuzumab

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Mammaplasty (Breast Reconstruction)
4.	Mastectomy (Mammectomy)
5.	VAP-cyclo protocol